

## Dicot recruits Mats Silvander as CTO

**Press release: Uppsala, May 3, 2023. Mats Silvander, PhD, has been recruited as Chief Technical Officer at the pharmaceutical company Dicot and will lead and develop the company's Supply Chain and IP work. The CTO role is a new management position within Dicot established to strengthen the company's internal capacity in strategically important areas.**

Uppsala-based Dicot is in an important phase where the company soon enters clinical trials with its potency drug candidate LIB-01. As part of strengthening the company's internal capacity, Mats Silvander, PhD, is now employed as CTO. Mats has over 20 years of industry experience from roles such as Director of Operations, CTO, Vice President Product Development and Quality Manager. He brings solid expertise in areas such as pharmaceutical manufacturing, supplier management, patent work and building and developing processes and effective teams. Mats comes most recently from the vaccine manufacturer Novavax AB and has previously worked at BioGaia, Paragon Nordic and Quinnova Pharmaceuticals, among others. Mats starts his position August 14.

*"We are very pleased to welcome Mats to our team. Mats' solid expertise will be an important building block to drive and develop our Supply Chain and IP work in the best way and in line with the business strategy. This recruitment is an important strategic step in our targeted work to continue building and professionalizing Dicot",* comments Elin Trampe, CEO of Dicot.

*"It is an honor to become part of a competent and driven company and it will be fantastic to be part of developing Dicot to the next level",* comments Mats Silvander, Dicot's new CTO.

### **For further information, please contact:**

Elin Trampe, CEO

Phone: +46 739 80 14 08

E-mail: [elin.trampe@dicot.se](mailto:elin.trampe@dicot.se)

### **About Dicot AB**

Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 7 billion. Dicot's strategy is to develop LIB-01 under own auspices until phase 2a studies and thereafter in partnership with larger, established pharmaceutical companies, finance and develop LIB-01 further to a registered pharmaceutical on the world market.

Dicot is listed on Spotlight Stock Market and has approximately 4,100 shareholders. For more information, please visit [www.dicot.se](http://www.dicot.se).

---